文献速递肝病

戒酒改善酒精性肝硬化各阶段门静脉高压患者的预后

Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-12-05

本研究纳入320例接受基线肝静脉压力梯度(HVPG)测量且HVPG≥10 mm Hg的酒精性肝硬化患者,中位随访36个月。戒酒与肝失代偿风险(aHR 0.391)、肝病相关死亡(aHR 0.428)及全因死亡(aHR 0.453)风险显著降低相关,且在HVPG 10-19 mm Hg和HVPG≥20 mm Hg两组中均显著降低肝失代偿累积发生率。

要点

  • 戒酒与肝失代偿风险显著降低相关(aHR 0.391,P < .001)。
  • 戒酒与肝病相关死亡(aHR 0.428)及全因死亡(aHR 0.453)风险显著降低相关。
  • HVPG 10-19 mm Hg组3年肝失代偿概率戒酒者32.4% vs 饮酒者60.0%。

核心结论

  • 戒酒改善酒精性肝硬化所有门静脉高压阶段的预后,包括已进展至高危门静脉高压的患者。

研究设计与样本

  • 研究纳入320例酒精性肝硬化患者,均接受基线HVPG测量并诊断为临床显著门静脉高压(HVPG≥10 mm Hg),中位年龄57岁(IQR 49.7-63.1),75.6%为男性,87.5%为失代偿期,中位HVPG 20 mm Hg(IQR 17-23),中位随访36个月(IQR 14-80)。

主要发现

  • 241例(75.3%)患者保持戒酒,79例(24.7%)患者有活跃饮酒。
  • 校正基线HVPG、MELD和既往失代偿后,戒酒与肝失代偿风险显著降低相关(aHR 0.391,P < .001)。
  • 戒酒与肝病相关死亡(aHR 0.428,P < .001)及全因死亡(aHR 0.453,P < .001)风险显著降低相关。
  • HVPG 10-19 mm Hg组3年肝失代偿概率戒酒者32.4% vs 饮酒者60.0%,HVPG≥20 mm Hg组戒酒者57.5% vs 饮酒者82.6%。
  • 戒酒在HVPG 10-19 mm Hg组(P < .001)和HVPG≥20 mm Hg组(P = .002)均显著降低肝失代偿累积发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Alcohol-related liver disease is a leading cause of liver-related mortality. The effect of alcohol abstinence on the natural history of alcohol-related cirrhosis across distinct stages of portal hypertension has not been thoroughly investigated. In this study, we assessed the clinical implications of abstinence in patients with alcohol-related cirrhosis and clinically significant portal hypertension. METHODS: Alcohol abstinence, hepatic decompensation, and mortality were assessed in patients with alcohol-related cirrhosis who underwent a baseline hepatic venous pressure gradient (HVPG) measurement and were diagnosed with clinically significant portal hypertension (HVPG ≥10 mm Hg). RESULTS: A total of 320 patients with alcohol-related cirrhosis (median age: 57 [interquartile range (IQR), 49.7-63.1] years; 75.6% male; 87.5% decompensated) and a median HVPG of 20 (IQR, 17-23) mm Hg were followed up for a median of 36 (IQR, 14-80) months. Overall, 241 (75.3%) patients remained abstinent, while 79 (24.7%) patients had active alcohol consumption. Alcohol abstinence was linked to a significantly reduced risk of hepatic decompensation (adjusted hazard ratio [aHR], 0.391; P < .001), as well as liver-related (aHR, 0.428; P < .001) and all-cause (aHR, 0.453; P < .001) mortality, after adjusting for baseline HVPG, MELD, and previous decompensation. Importantly, alcohol abstinence significantly reduced the cumulative incidence of hepatic decompensation in both groups with HVPG 10-19 mm Hg (P < .001) and HVPG ≥20 mm Hg (P = .002). The 3-year decompensation probability was 32.4% vs 60.0% in HVPG 10-19 mm Hg and 57.5% vs 82.6% in HVPG ≥20 mm Hg for abstinent patients vs active drinkers, respectively. CONCLUSIONS: Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis, including in patients who have already progressed to high-risk portal hypertension. (ClinicalTrials.gov, Number: NCT03267615).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hofer BS, Simbrunner B, Hartl L, et al. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis. Clin Gastroenterol Hepatol. 2022. PMID: 36481475. doi:10.1016/j.cgh.2022.11.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。